Commentary:Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis by Zeng, Boning et al.
GENERAL COMMENTARY
published: 27 August 2020
doi: 10.3389/fimmu.2020.01925
Frontiers in Immunology | www.frontiersin.org 1 August 2020 | Volume 11 | Article 1925
Edited by:
Marina Cella,
Washington University School of
Medicine in St. Louis, United States
Reviewed by:
Giuseppe Sciumè,
Sapienza University of Rome, Italy
Massimo Vitale,
Azienda Ospedaliera Universitaria San
Martino (IRCCS), Italy
*Correspondence:
Feiyue Xing
tfyxing@jnu.edu.cn
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
NK and Innate Lymphoid Cell Biology,
a section of the journal
Frontiers in Immunology
Received: 04 May 2020
Accepted: 17 July 2020
Published: 27 August 2020
Citation:
Zeng B, Xing R, Dong C and Xing F
(2020) Commentary: Group 3 innate
lymphoid cells mediate early protective
immunity against tuberculosis.
Front. Immunol. 11:1925.
doi: 10.3389/fimmu.2020.01925
Commentary: Group 3 innate
lymphoid cells mediate early
protective immunity against
tuberculosis
Boning Zeng 1,2†, Rui Xing 3†, Changjiang Dong 4 and Feiyue Xing 1,2*
1Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, China,
2MOE Key Laboratory of Tumor Molecular Biology, Key Laboratory of Functional Protein Research of Guangdong, Higher
Education Institutes, Jinan University, Guangzhou, China, 3MOE Key Laboratory of Protein Sciences, Tsinghua-Peking Center
for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China, 4 BioMedical Research Center, University of
East Anglia, Norwich, United Kingdom
Keywords: group 3 innate lymphoid cell, pulmonary tuberculosis, mycobacterium tuberculosis, CXCR5, CXCL13,
iBALT
A Commentary on
Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis
by Ardain, A., Domingo-Gonzalez, R., Das, S., Kazer, S. W., Howard, N. C., Singh, A., et al. (2019)
Nature 570:528–32. doi: 10.1038/s41586-019-1276-2
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a leading cause of mortality,
surpassing any other single infectious disease. Two billion people are infected withMtb worldwide
with 1.7 million deaths each year (1). One of the most critical factors leading to the global epidemic
of TB is lack of adequate and safe vaccines. Although the current only licensed TB vaccine, Bacille
Calmette-Guérin (BCG), can prevent Mtb infection in infants and young children, it can only
provide partial and inconsistent protection (0–70%) to populations (1, 2). Most studies showed
that BCG vaccination protection against tuberculosis lasts for up to 10 years, waning with time
(3). Moreover, mounting explosion of drug-resistant TB and TB/HIV co-infection poses a serious
threat to treatment and further prevention of the diseases (4, 5). Over the past decade, a worldwide
collaborative effort to develop a novel preventive and/or therapeutic TB vaccine is unfortunately
disappointing. Although some encouraging progress has been made, developing a vaccine more
effective than BCG, and a new therapeutic strategy for treatment, remains an ongoing challenge,
especially due to lack of crucial biomarkers and poor understanding of the mechanistic processes
involving innate and adaptive immunity in the protection against this disease (4, 6).
Innate immunity against TB is very crucial in the control of early Mtb infection especially by
pulmonary immune responses, which is mainly carried out by alveolar innate immune cells, such
as macrophages, dendritic cells, monocytes, and neutrophils. Adaptive immunity against TB is
also executed by Th1 and Th17 cells with TNF-α, IFN-γ, IL-17, and IL-22. Both IL-17 and IL-
22 can recruit neutrophils, and activate macrophages, IFN-γ-producing CD8+ T cells, γδT cells
with perforin and granulysin as well as other T lymphocytes, including NKT and CD1-restricted
αβT cells (7, 8). Additionally, B cells in Mtb-infected lungs are also able to combat Mtb especially
through generation of specific or nonspecific antibodies in a T cell-dependent or independent
manner. They presentMtb antigens to Th cells, such as Th1, Th17, and Tfh cells. The latter release
IFN-α and IFN-β to function, facilitate neutrophil migration via regulating Th17 cells to produce
IL-17, and polarize lung macrophages (9).
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Recently, a ground-breaking study on group 3 innate
lymphoid cells (ILC3s) was reported in Nature (10). Ardain
et al. (10) reveal for the first time that ILC3s mediate an early
protective role in immunity to Mtb infection in lungs through
generation of IL-17 and IL-22 in a C-X-Cmotif chemokine ligand
13 (CXCL13)–C-X-C motif chemokine receptor 5 (CXCR5)-
dependent manner with formation of inducible bronchus-
associated lymphoid tissue (iBALT) structures, providing a novel
insight into the mechanistic process of interaction between TB
infection and innate immune cells (Figure 1).
Recognized only in the past decade, ILCs have been currently
classified into group 1 innate lymphoid cells (ILC1s), natural
killer (NK) cells, group 2 innate lymphoid cells (ILC2s),
ILC3s, lymphoid-tissue-inducer (LTi) cells, and regulatory innate
lymphoid cells (ILCregs) on the basis of their development,
phenotype, and function (11–13). ILC1smainly produce the Th1-
type cytokine IFN-γ. ILC2s secrete Th2-type cytokines, such
as interleukin (IL)-4, IL-5, IL-9, and IL-13. ILC3s, including
natural cytotoxicity receptor-negative (NCR−) and NCR+ ILC3s,
primarily produce IL-17 and IL-22, like Th17 and Th22 cells.
NK cells functionally represent the counterpart of the CD8+
cytotoxic T cells. Finally, ILCregs release both IL-10 and TGF-
β to mirror the functions of Tregs (11, 14, 15). It is well-
known that ILC3s exist mainly in intestinal mucosa, epithelial
tissue, and skin, which are considered to function in tissue repair
and mucosal homeostasis, whereas ILC2s are largely located
FIGURE 1 | Regulatory role of ILC3s in early pulmonary tuberculosis. ILC3s move from blood to lung, and recruit immune cells through the IL-17 and IL-22 to form
iBALT structures in a CXCL13-CXCR5-dependent manner, exerting an early protective effect on Mtb infection. DC, dendritic cells; FDC, follicular dendritic cells; HEV,
high endothelial venules; iBALT, inducible bronchus-associated lymphoid tissues.
in lung, skin, adipose tissue, and peripheral lymphatic tissues,
which enable these tissues and organs to defend against helminth
infection and allergen invasion.
The involvement of ILC3s in respiratory diseases is, to date,
less well-defined. Inspiringly, Ardain et al. findings, that ILC3s
but not ILC2s can protect lung tissue from Mtb early infection,
make us regain recognition of novel actions of ILC3s in lungs.
Importantly, they can initiate not only a rapid, non-specific
response to extracellular microbes, but also a protection against
intracellular specific pathogenMtb, which is regarded as a crucial
regulator in tissue homeostasis and inflammatory response (12).
In this study, the researchers observed that the population
of ILCs, including the ILC3s, was highly exhausted in Mtb-
infected patients compared to healthy individuals. Intriguingly,
the number of ILC1s and ILC3s, but not ILC2s, restored
upon treatment, indicating that Mtb bacteremia can modulate
the accumulation of ILCs. Using human and mouse models
of Mtb infection, they found that the accumulation of ILC3s
synchronizes with alveolar macrophages increased in the lungs to
reinforceMtb control. The authors also tracked the localization of
ILCs in several animal models and discovered that in the mice
with intact immune system ILC3s migrate from the blood to
the lung, homing to infected lung tissue, and produce messenger
molecules IL-17 and IL-22. These cytokines are critical inducers
of CXCL13 to recruit immune cells to form iBALT-associated
granuloma structures in a CXCL13-CXCR5-dependent manner
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(Figure 1). Additionally, ILC3s are also able to inhibit Mtb
growth in a phagolysosomal fusion manner (16).
CXCL13, one of the members of the CXC-chemokine family,
is usually expressed by stromal cells, follicular dendritic cells
(FDCs) and CD11c+ DCs during Mtb infection (17). In fact,
increasing evidence supports that a CXCL13-CXCR5 axis is
associated with the formation of iBALT (17, 18). iBALT consists
principally of separated B cell areas containing FDCs, T cell
regions containing DCs, high endothelial venules (HEVs),
specialized stromal cells as well as lymphatic vessels (18, 19).
Consistent with these reports, Ardain et al. found that the level of
CXCL13 was elevated inMtb-infected mice and patients with TB.
Furthermore, the expression of CXCR5, a receptor of CXCL13,
on the surface of ILC3s was also upregulated, suggesting that
the CXCL13-CXCR5 axis might be involved in the regulation
of Mtb infection by ILC3s (10). Additionally, ILC3s appear
highly heterogeneous. Phenotypic characteristics of NCR− ILC3s
include Lin−, CCR6+, NKp44− (in humans), CD25+, CD117+,
CD127+, and CD161+, but NCR+ ILC3s present NKp44+ and
NKp30+, which is entirely discriminated from NCR− ILC3s (8).
Thus, it deserves to be further studied what is a regulatory role
of each ILC3 subpopulation in TB infection. Noteworthily, in
the lungs of immunodeficient mice without functional ILCs the
number of macrophages was decreased with the poor immune
control of TB, which demonstrates thatmacrophages canmediate
especially activation of ILC3s through IL-1β.
On the other hand, intestinal CD103+CD11b+ DCs instruct
the lung-specific trafficking of circulating IL-22+ ILC3s via
boosting the lung-homing receptor CCR4 expression on IL-22+
ILC3s. The CCR4 is recruited by chemokine CCL17 or CCL20
generated by pulmonary epithelium cells (20). Ly6ClowCD11b+
activated monocytes increases the frequency of IL-17+ ILC3s in
the lungs of K. pneumonia-infected mice via producing TNF-
α that markedly up-regulates the level of CCL20 in the lung
epithelial cells (21). It is well-known that NCR+ ILC3s primarily
express IL-22, but NCR− ILC3s predominantly produce IL-
17 (12). Consequently, it deserves to be investigated how
NCR− ILC3s home to the lungs, and whether pulmonary
CD103+CD11b+ DCs function in lung-selective migration of
NCR+ ILC3s.
Above all, ILC3s play a pivotal and previously
underappreciated role in pulmonary TB immunity. They
mainly mediate body’s early defense against TB infection
through the IL-17/IL-22 axis in a CXCL13-CXCR5-dependent
manner with formation of iBALT, which bridges a gap between
innate immune cells and adaptive immune responses and
advances our understanding of pathogenesis of TB. During
Mtb infection, stromal cells, FDCs, and B cells express CXCL13
in iBALT, by which circulating CXCR5-expressing ILC3s are
attracted into the lungs to mediate protective immunity from
Mbt (18). The breakthrough discovery not only opens a door
to research on ILCs for their regulating TB infection, but
also paves a way to develop a potential treatment regimen
for TB or especially drug-resistant TB. We reasonably infer
that this early protective effect of ILC3s would appear in
intestinal Mtb infection. However, how to target ILC3s or their
secreted functional molecules, which contributes to the body
to resist Mtb invasion, needs further exploration. Besides, BCG
vaccination in animals unexpectedly initiates a rapidly strong
recruitment of ILC3s that confer a protective immune response
to Mtb in the lungs via the intranasal route administration,
suggesting that there exist lung memory-like ILC3s (22). Hence,
ILC3s play an important part in protective immunity against
TB beyond our current recognition. We imagine that the
memory-like ILC3s might be developed as potential vaccines in
the future.
AUTHOR CONTRIBUTIONS
FX conceived of this commentary. BZ and FX drafted it. CD
was responsible for the critical reading. FX and RX revised and
finalized the manuscript. All the authors read and approved the
final manuscript.
FUNDING
This work was supported by the National Natural Science
Foundation of China (grant number 81172824) and Guangzhou
City Science and Technology Program Synergistic Innovation
Major Project (grant number 201604020146) to FX.
REFERENCES
1. Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MHN, Hughes
TK, et al. Prevention of tuberculosis in macaques after intravenous BCG
immunization. Nature. (2020) 577:95–102. doi: 10.1038/s41586-019-1817-8
2. Gupta N, Kumar R, Agrawal B. New players in immunity to tuberculosis: the
host microbiome, lung epithelium, and innate immune cells. Front Immunol.
(2018) 9:709. doi: 10.3389/fimmu.2018.00709
3. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al.
Systematic review and meta-analysis of the current evidence on the duration
of protection by bacillus Calmette-Guerin vaccination against tuberculosis.
Health Technol Assess. (2013) 17:1–372. doi: 10.3310/hta17370
4. Hunter R, Actor J. The pathogenesis of post-primary tuberculosis. A game
changer for vaccine development. Tuberculosis (Edinb). (2019) 116S:S114–
17. doi: 10.1016/j.tube.2019.04.018
5. Dheda K, Limberis JD, Pietersen E, Phelan J, Esmail A, Lesosky M, et al.
Outcomes, infectiousness, and transmission dynamics of patients with
extensively drug-resistant tuberculosis and home-discharged patients
with programmatically incurable tuberculosis: a prospective cohort
study. Lancet Resp Med. (2017) 5:269–81. doi: 10.1016/S2213-2600(16)3
0433-7
6. Ernst JD. Mechanisms of M. tuberculosis immune evasion as
challenges to TB vaccine design. Cell Host Microbe. (2018)
24:34–42. doi: 10.1016/j.chom.2018.06.004
7. Etna MP, Giacomini E, Severa M, Coccia EM. Pro- and anti-inflammatory
cytokines in tuberculosis: a two-edged sword in TB pathogenesis. Semin
Immunol. (2014) 26:543–51. doi: 10.1016/j.smim.2014.09.011
8. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S,
et al. Immunological mechanisms of human resistance to persistent
Mycobacterium tuberculosis infection. Nat Rev Immunol. (2018) 18:575–
89. doi: 10.1038/s41577-018-0025-3
9. Dyatlov AV, Apt AS, Linge IA. B lymphocytes in anti-mycobacterial
immune responses: pathogenesis or protection? Tuberculosis. (2019) 114:1–
8. doi: 10.1016/j.tube.2018.10.011
Frontiers in Immunology | www.frontiersin.org 3 August 2020 | Volume 11 | Article 1925
Zeng et al. ILC3s Control Early Pulmonary Tuberculosis
10. Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A,
et al. Group 3 innate lymphoid cells mediate early protective immunity against
tuberculosis. Nature. (2019) 570:528–32. doi: 10.1038/s41586-019-1276-2
11. Zeng B, Shi S, Liu J, Xing F. Commentary: regulatory innate lymphoid
cells control innate intestinal inflammation. Front Immunol. (2018)
9:1522. doi: 10.3389/fimmu.2018.01522
12. Zeng BN, Shi SN, Ashworth G, Dong CJ, Liu J, Xing FY. ILC3 function as a
double-edged sword in inflammatory bowel diseases. Cell Death Dis. (2019)
10:315. doi: 10.1038/s41419-019-1540-2
13. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl
G, et al. Innate lymphoid cells: 10 years on. Cell. (2018) 174:1054–
66. doi: 10.1016/j.cell.2018.07.017
14. Colonna M. Innate lymphoid cells: diversity, plasticity, and
unique functions in immunity. Immunity. (2018) 48:1104–
17. doi: 10.1016/j.immuni.2018.05.013
15. Zook EC, Kee BL. Development of innate lymphoid cells.Nat Immunol. (2016)
17:775–82. doi: 10.1038/ni.3481
16. Ardain A, Porterfield JZ, Kloverpris HN, Leslie A. Type 3 ILCs in
lung disease. Front Immunol. (2019) 10:92. doi: 10.3389/fimmu.201
9.00092
17. Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA,
Mehra S, et al. CXCR5(+) T helper cells mediate protective immunity
against tuberculosis. J Clin Invest. (2013) 123:712–26. doi: 10.1172/JC
I65728
18. Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated
lymphoid tissue: taming inflammation in the lung. Front Immunol. (2016)
7:258. doi: 10.3389/fimmu.2016.00258
19. Hirahara K, Shinoda K, Morimoto Y, Kiuchi M, Aoki A, Kumagai
J, et al. Immune cell-epithelial/mesenchymal interaction contributing to
allergic airway inflammation associated pathology. Front Immunol. (2019)
10:570. doi: 10.3389/fimmu.2019.00570
20. Gray J, Oehrle K, Worthen G, Alenghat T, Whitsett J, Deshmukh
H. Intestinal commensal bacteria mediate lung mucosal immunity and
promote resistance of newborn mice to infection. Sci Transl Med. (2017)
9:eaaf9412. doi: 10.1126/scitranslmed.aaf9412
21. Xiong H, Keith JW, Samilo DW, Carter RA, Leiner IM, Pamer EG. Innate
lymphocyte/Ly6C(hi) monocyte crosstalk promotes klebsiella pneumoniae
clearance. Cell. (2016) 165:679–89. doi: 10.1016/j.cell.2016.03.017
22. Choreno-Parra JA, Weinstein LI, Yunis EJ, Zuniga J, Hernandez-Pando
R. Thinking outside the box: innate- and B cell-memory responses as
novel protective mechanisms against tuberculosis. Front Immunol. (2020)
11:226. doi: 10.3389/fimmu.2020.00226
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Zeng, Xing, Dong and Xing. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 4 August 2020 | Volume 11 | Article 1925
